DealsJul 20, 2026, 07:02 AM
Kamada Secures $50M Plasma Supply Deal Over 3 Years
AI Summary
Kamada Ltd. announced a new three-year agreement to supply normal source plasma to a leading biopharmaceutical company. This deal is projected to generate approximately $50 million in revenue over three years, with initial sales expected in the fourth quarter of 2026. The company stated that the agreement validates its investment in U.S.-based plasma collection centers and supports its vertical-integration strategy and revenue growth objectives.
Key Highlights
- Kamada secured a new three-year agreement to supply plasma.
- The agreement is expected to generate approximately $50 million in revenue.
- Initial commercial sales are anticipated to be recorded in Q4 2026.
- The deal validates investment in Kamada's U.S. plasma collection centers.
- It supports Kamada's vertical-integration strategy and revenue growth.
- Kamada's Houston and San Antonio centers have 50,000 liters/year capacity each.
- Expected Q4 sales from this agreement are included in current annual guidance.
Price Impact
More from KMDA